Private Equity Firms Target Active Pharmaceutical Ingredients Sector
Private equity firms including Astorg, EQT, New Mountain Capital, and TA Associates are engaging in a series of transactions in the active pharmaceutical ingredients (API) sector, focusing on buying and selling assets. According to PE Hub, these firms have participated in five deals, reflecting interest in the sector’s potential for growth within healthcare.
Overview of PE Activity in API
The active pharmaceutical ingredients sector involves the biologically active components in medications, attracting private equity firms seeking opportunities in healthcare. Firms like Astorg, EQT, New Mountain Capital, and TA Associates are involved in transactions that include acquiring and selling API assets. According to PE Hub, these activities align with broader patterns in the pharmaceutical industry, where firms target subsectors with stable revenue and demand for essential drug components. The deals enable portfolio optimization and value extraction, as firms position themselves in global supply chains.
Key Deals and Firms Involved
Five deals in the API sector have featured participation from Astorg, EQT, New Mountain Capital, and TA Associates, as noted by PE Hub. These transactions consist of acquisitions and sales, allowing firms to navigate sector dynamics. Astorg, with its history in healthcare investments, is among those involved, likely targeting high-demand areas like API production. EQT and New Mountain Capital are also participating, alongside TA Associates, in these competitive efforts to expand exposure. While specific transaction details remain limited, the involvement underscores a strategic focus on API as part of healthcare investments.
